Oxysterols and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11279730-B2
Application number	US-202016943649-A
Country	US
Kind code	B2
Filing date	Jul 30, 2020
Priority date	Jul 7, 2016
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , R 3 and R 6 , R 11a , and R 11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

First claim

What is claimed is:

1. A method for treating a CNS-related condition in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or C 1 -C 6 alkyl;
each of R 2 and R 3 is independently hydrogen, C 1 -C 6 alkyl, or carbocyclyl, or R 2 and R 3 , together with the carbon atom to which they are attached, form a 3-8 membered ring;
R 6 is absent or hydrogen;
R 11a is hydrogen or C 1 -C 6 alkyl and R 11b is —OH, or C 1 -C 6 alkyl, or R 11a and R 11b are joined together to form oxo; and
represents a single or double bond, wherein when one is a double bond, the other is a single bond; and when one of the is a double bond, R 6 is absent; or

a pharmaceutical composition comprising said compound of Formula (I) or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
wherein the CNS-related condition is related to NMDA-modulation and is selected from the group consisting of schizophrenia, psychotic disorders, sleep disorder, autism spectrum disorders, multiple sclerosis, cognitive disorders, movement disorders, attention deficit disorder, attention deficit hyperactivity disorder, metabolic encephalopathies, postpartum psychosis, Smith Lemli-Opitz syndrome, and Niemann-Pick C disorder.

2. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-A) or Formula (I-B):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (II-A) or Formula (II-B):

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:

5. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of a compound selected from the group consisting of:

6. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (III):

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the CNS-related condition is selected from the group consisting of schizophrenia, psychotic disorders, sleep disorder, autism spectrum disorders, multiple sclerosis, movement disorders, attention deficit disorder, attention deficit hyperactivity disorder, metabolic encephalopathies, and postpartum psychosis.

8. The method of claim 7 , wherein the CNS-related condition is a movement disorder.

9. The method of claim 8 , wherein the movement disorder is selected from Huntington's Disease and Parkinson's disease.

10. The method of claim 1 , wherein the CNS-related condition is a cognitive disorder.

11. The method of claim 10 , wherein the cognitive disorder is selected from Alzheimer's disease and dementia.

12. The method of claim 11 , wherein the dementia is selected from cortical-basal dementia, progressive supranuclear palsy, frontal-temporal dementia, primary progressive aphasia, Parkinson's disease dementia, and Lewy body dementia.

13. The method of claim 1 , wherein the CNS-related condition is selected from the group consisting of Smith Lemli-Opitz syndrome, and Niemann-Pick C disorder.

Assignees

• Sage Therapeutics Inc

Inventors

• Salituro Francesco G
• Robichaud Albert Jean
• Martinez Botella Gabriel
• Harrison Boyd L
• Griffin Andrew
• La Daniel

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title